Patent Publication Number: US-2022219009-A1

Title: Irradiation device and treatment method

Description:
CROSS-REFERENCES TO RELATED APPLICATIONS 
     This application is a continuation of International Application No. PCT/JP2020/037150 filed on Sep. 30, 2020, which claims priority to Japanese Application No. 2019-180489 filed on Sep. 30, 2019, the entire content of both of which is incorporated herein by reference. 
    
    
     FIELD OF THE DISCLOSURE 
     The present disclosure relates to an irradiation device used for treatment of cervical cancer and a treatment method for cervical cancer. 
     BACKGROUND DISCUSSION 
     The number of patients with cervical cancer has an increasing tendency, and in particular, the number of young female patients in their 20s and 30s is increasing. In current treatment of cervical cancer, a standard treatment is to remove an entire uterus from an early stage (stage I), however, for younger patients, a local treatment is desired to preserve the uterus in order to maintain fertility. Further, in an advanced stage (stage III and subsequent stages), when cancer has spread to surrounding tissues and is difficult to remove by surgery, and thus a standard treatment is to combine radiation therapy and chemotherapy. However, a five-year survival rate can be as low as 50% in stage III and 20% in stage IV, and more effective treatment is desired. As the local treatment for cancer, a treatment method using a photoreactive substance is known. In particular, a treatment method using an antibody-photosensitive substance (hydrophilic phthalocyanine) can specifically kill target cells without killing non-target cells such as normal cells by irradiating the antibody-photosensitive substance accumulated in tumor with near-infrared light, and can be expected to achieve a high treatment effect while reducing side effects. 
     Meanwhile, in order to achieve a high treatment effect by the antibody-photosensitive substance, the antibody-photosensitive substance adsorbed to the tumor is required to be reliably irradiated with near-infrared light. However, near-infrared light has a small penetration depth, and thus can be difficult to deliver from a body surface to a solid cancer in a relatively noninvasive manner. Accordingly, it would be desirable to have a method for reliably irradiating a tumor in a body with light with reduced invasiveness. In the case of cervical cancer, cancer often spreads over a wide area of a cervical canal, and a method for irradiating cancer in a relatively wide range with light from as close as possible is required. Further, depending on the advanced stage, cancer may reach a pelvic wall, in which case it is difficult for light to approach the pelvic wall by a minimally invasive method that is transvaginal or uses a laparoscope. For example, U.S. Patent Application Publication No. 2018/0113246 discloses a method of transvascularly inserting an elongated device including an optical fiber to a position near a tumor so as to emit light from the inside of a blood vessel. 
     SUMMARY 
     An irradiation device and a treatment method capable of effectively irradiating an antibody-photosensitive substance bound to cell membranes of cervical cancer with near-infrared light are disclosed. 
     In accordance with one aspect, a treatment method is disclosed for cervical cancer, including: intravenously administering an antibody-light-absorbing substance; inserting a first irradiation device, including a first optical fiber and an orientation marker, into a uterine artery 12 hours to 36 hours after the intravenous administration; advancing the first irradiation device to a target position while confirming a position of the first irradiation device with the orientation marker; emitting near-infrared light by using the first optical fiber in a direction substantially perpendicular to the first optical fiber; removing the first irradiation device out of a body; inserting a second irradiation device, which is the first irradiation device or another irradiation device, from a vagina into a cervix; performing irradiation by using a second optical fiber included in the second irradiation device in a direction substantially perpendicular to the second optical fiber; drawing at least a part of a deformation portion included in the second irradiation device to an external uterine ostium and inflating the deformation portion so as to follow a shape of an organ; emitting near-infrared light by using the second optical fiber in a substantially distal direction and/or the direction substantially perpendicular to the second optical fiber; and contracting the deformation portion. 
     In the treatment method configured as described above, the first irradiation device is inserted into the uterine artery to emit near-infrared light from the inside of a blood vessel in the substantially vertical direction, so that a tissue or an organ infiltrated with cancer cells near the uterine artery can be effectively irradiated with near-infrared light. Further, in this treatment method, the second irradiation device is inserted into the cervix to emit near-infrared light in the substantially vertical direction, so that cancer cells in the cervix can be effectively irradiated with near-infrared light from a lumen of the cervix. Furthermore, in this treatment method, the deformation portion drawn from the external uterine ostium is inflated to emit near-infrared light in the distal direction and/or the vertical direction, so that cancer cells near the uterine vagina can be effectively irradiated with near-infrared light. Therefore, in this treatment method, the antibody-photosensitive substance bound to cell membranes of cervical cancer can be effectively irradiated with near-infrared light. 
     In accordance with another aspect, a treatment method is disclosed for cervical cancer, including: intravenously administering an antibody-light-absorbing substance; inserting a first irradiation device, including a first optical fiber and an orientation marker, into a uterine artery 12 hours to 36 hours after the intravenous administration; advancing the first irradiation device to a target position while confirming a position of the first irradiation device with the orientation marker; emitting near-infrared light by using the first optical fiber in a direction substantially perpendicular to the first optical fiber; removing the first irradiation device out of a body; inserting a second irradiation device, which is the first irradiation device or another irradiation device, from a vagina into a cervix; inflating a deformation portion included in the second irradiation device so as to follow a shape of an organ; emitting near-infrared light by using a second optical fiber in a substantially distal direction and/or a direction substantially perpendicular to the second optical fiber; and contracting the deformation portion. 
     In the treatment method configured as described above, the first irradiation device is inserted into the uterine artery to emit near-infrared light from the inside of a blood vessel in the substantially vertical direction, so that a tissue or an organ infiltrated with cancer cells near the uterine artery can be effectively irradiated with near-infrared light. Further, in this treatment method, the second irradiation device is inserted into the cervix and the deformation portion is inflated to emit near-infrared light in the distal direction and/or the vertical direction, so that a wide range of cervical cancer in the cervix can be effectively irradiated with near-infrared light. Therefore, in this treatment method, the antibody-photosensitive substance bound to cell membranes of cervical cancer can be effectively irradiated with near-infrared light. 
     In another aspect, a treatment method is disclosed for cervical cancer, including: intravenously administering an antibody-light-absorbing substance; inserting a second irradiation device including a second optical fiber from a vagina into a cervix 12 hours to 36 hours after the intravenous administration; performing irradiation by using the second optical fiber included in the second irradiation device in a direction substantially perpendicular to the second optical fiber; drawing at least a part of a deformation portion included in the second irradiation device to an external uterine ostium and inflating the deformation portion so as to follow a shape of an organ; emitting near-infrared light by using the second optical fiber in a substantially distal direction and/or the direction substantially perpendicular to the second optical fiber; and contracting the deformation portion. 
     In the treatment method configured as described above, the second irradiation device is inserted into the cervix to emit near-infrared light in the substantially vertical direction, so that cancer cells in the cervix can be effectively irradiated with near-infrared light from a lumen of the cervix. Furthermore, in this treatment method, the deformation portion drawn from the external uterine ostium is inflated to emit near-infrared light in the distal direction and/or the vertical direction, so that cancer cells near the uterine vagina can be effectively irradiated with near-infrared light. Therefore, in this treatment method, the antibody-photosensitive substance bound to cell membranes of the cancer cells of the cervix and a tissue or an organ infiltrated from the cervix in a vertical direction can be effectively irradiated with near-infrared light. 
     In another aspect of the treatment method according to the disclosure that may be a treatment method for cervical cancer, including: intravenously administering an antibody-light-absorbing substance; inserting a second irradiation device including a second optical fiber from a vagina into a cervix 12 hours to 36 hours after the intravenous administration; inflating a deformation portion included in the second irradiation device so as to follow a shape of an organ; emitting near-infrared light by using the second optical fiber in a substantially distal direction and/or a direction substantially perpendicular to the second optical fiber; and contracting the deformation portion. 
     In the treatment method configured as described above, the second irradiation device is inserted into a cervical canal and the deformation portion is inflated to emit near-infrared light in the distal direction and/or the vertical direction, so that a wide range of cancer cells in the cervix can be effectively irradiated with near-infrared light. Therefore, in this treatment method, the antibody-photosensitive substance bound to cell membranes of the cancer cells in the cervix and a tissue or an organ infiltrated from the cervix in a vertical direction can be effectively irradiated with near-infrared light. 
     In this treatment method, in the inflating the deformation portion, a part of the deformation portion may be inflated so as to follow a shape of the uterine vagina on a side proximal of the external uterine ostium. Accordingly, in this treatment method, the antibody-photosensitive substance bound to cell membranes of the cancer cells in the cervix including the uterine vagina and the tissue or the organ infiltrated downward of the cervix can be effectively irradiated with near-infrared light. 
     In this treatment method, in the inflating the deformation portion, a proximal portion of the deformation portion may be inflated so as to follow the shape of the uterine vagina on the side proximal of the external uterine ostium, and a distal portion of the deformation portion may be inflated so as to follow a shape of a uterine cavity on a side distal of an internal cervical ostium. Accordingly, in this treatment method, the antibody-photosensitive substance bound to the cell membranes of the cancer cells in the cervix and the tissue or the organ infiltrated from the cervix in the vertical direction can be effectively irradiated with near-infrared light. 
     In this treatment method, rotating the second irradiation device, the inflating the deformation portion so as to follow the shape of the organ, the emitting near-infrared light by using the second optical fiber in the distal direction and/or the direction substantially perpendicular to the second optical fiber, and the contracting the deformation portion may be repeated at least once after the contracting the deformation portion. Accordingly, in this treatment method, a wide area of the cervix in a circumferential direction can be irradiated with near-infrared light. 
     The second irradiation device may be identical to the first irradiation device. Accordingly, in this treatment method, the irradiation with near-infrared light from the uterine artery and the irradiation with near-infrared light from the cervix can be performed by one irradiation device. Therefore, this treatment method can help improve medical economics. 
     In this treatment method, after the removing the first irradiation device out of the body, the first irradiation device may be washed. Accordingly, in this treatment method, blood attached to the first irradiation device inserted into the blood vessel is removed, and the first irradiation device can be placed in a desirable state to be inserted from the vagina into the cervix. 
     In this treatment method, the inflating the deformation portion included in the first irradiation device may be performed before the emitting near-infrared light by using the first optical fiber, and the contracting the deformation portion included in the first irradiation device may be performed after the emitting near-infrared light by using the first optical fiber. Accordingly, when emitting near-infrared light from the first irradiation device in the uterine artery, blood flow in the uterine artery can be blocked. Therefore, an influence of the blood on near-infrared light can be reduced, and a target site can be effectively irradiated with near-infrared light. 
     In accordance with an aspect, the irradiation device according to the disclosure is an irradiation device configured to be used for treatment of cervical cancer, and, configured to be used for photoimmunotherapy of killing a cancer cell by irradiating an antibody-photosensitive substance bound to a cell membrane of the cancer cell with near-infrared light. The irradiation device can include: an elongated shaft portion; a balloon provided at a distal portion of the shaft portion and configured to inflate; an optical fiber; and an irradiation unit provided at a distal end of the optical fiber, arranged inside the balloon, and configured to emit light. The irradiation unit is configured to emit light in a direction substantially perpendicular to an axis of the optical fiber and in a substantially distal direction. 
     The irradiation unit may be configured to emit light in a state where the balloon is contracted and in a state where the balloon is inflated. 
     The balloon may be provided inside with an X-ray opaque orientation marker. 
    
    
     
       BRIEF DESCRIPTION OF THE DRAWINGS 
         FIG. 1  is a plan view illustrating an irradiation device used in a treatment method according to a first embodiment. 
         FIG. 2  is a cross-sectional view illustrating a distal portion of the irradiation device. 
         FIG. 3  is a schematic view illustrating a state in a body when the irradiation device is inserted into a uterine artery in the treatment method according to the first embodiment. 
         FIG. 4  is a schematic cross-sectional view for illustrating a state where near-infrared light is emitted by using the irradiation device inserted into the uterine artery. 
         FIGS. 5A and 5B  are schematic views illustrating the irradiation device inserted into a cervix from a vagina, in which  FIG. 5A  illustrates a state where near-infrared light is emitted from the cervix, and  FIG. 5B  illustrates a state where a deformation portion drawn from an external uterine ostium is deformed to emit near-infrared light. 
         FIG. 6  is a schematic view illustrating a state where near-infrared light is emitted by using an irradiation device inserted into a cervix from a vagina in a treatment method according to a second embodiment. 
         FIGS. 7A and 7B  are plan views illustrating a first modification of the irradiation device, in which  FIG. 7A  illustrates a state before a deformation portion is deformed, and  FIG. 7B  illustrates a state where the deformation portion is deformed. 
         FIGS. 8A and 8B  are plan views illustrating a second modification of the irradiation device, in which  FIG. 8A  illustrates a state before the deformation portion is deformed, and  FIG. 8B  illustrates a state where the deformation portion is deformed. 
         FIGS. 9A and 9B  are plan views illustrating a third modification of the irradiation device, in which  FIG. 9A  illustrates a state before the deformation portion is deformed, and  FIG. 9B  illustrates a state where the deformation portion is deformed. 
     
    
    
     DETAILED DESCRIPTION 
     Set forth below with reference to the accompanying drawings is a detailed description of embodiments of an irradiation device used for treatment of cervical cancer and a treatment method for cervical cancer representing examples of the inventive irradiation device used for treatment of cervical cancer and treatment method for cervical cancer. For convenience of explanation, dimensions in the drawings may be exaggerated and may be different from actual dimensions. In the present specification and the drawings, components having substantially the same functional configuration are designated by the same reference numerals, and a duplicate description of the components having substantially the same functional description will be omitted. In the present specification, a side to be inserted into a body lumen of a device is referred to as a “distal side”, and a side to be operated is referred to as a “proximal side”. 
     First Embodiment 
     A treatment method according to a first embodiment is a treatment method for cervical cancer, and is a treatment method related to photoimmunotherapy of killing cancer cells by irradiating an antibody-photosensitive substance bound to cell membranes of the cancer cells with near-infrared light. In this treatment method, the antibody-photosensitive substance, which is obtained by binding an antibody that specifically binds to only a specific antigen on surfaces of the cancer cells and a photosensitive substance paired with the antibody, is used as a drug. The antibody is not particularly limited, and may be, for example, panitumbab, trastuzumab, HuJ591, and the like. The photosensitive substance can be, for example, hydrophilic phthalocyanine which is a substance that reacts with near-infrared light having a wavelength of about 700 nm (IR700), but is not limited to hydrophilic phtaalocyanine. IR 700, for example, is capable of killing the cancer cells by absorbing light upon reception of near-infrared light having a wavelength having a peak in the vicinity of 700 nm, and causing a chemical change to form a hole in the cell membrane. 
     In the treatment method according to the first embodiment, in order to transvascularly and transvaginally irradiate the antibody-photosensitive substance bound to the cancer cells with near-infrared light, an irradiation device  10  that can be inserted into a blood vessel and a cervix is used, as illustrated in  FIG. 1 . First, the irradiation device  10  will be described. 
     As illustrated in  FIGS. 1 and 2 , the irradiation device  10  can include an elongated shaft portion  20 , a balloon  30  which is a deformation portion provided at a distal portion of the shaft portion  20 , a hub  40  connected to a proximal portion of the shaft portion  20 , orientation markers  50 , and an optical fiber  60 . The irradiation device  10  is used by being connected to a light output device  70 . 
     The shaft portion  20  can include an outer tube  21  which is a tubular body having a distal end and a proximal end, the distal end and the proximal end being open, and an inner tube  22  disposed inside the outer tube  21 . An inflation lumen  23  through which an inflation fluid for inflating the balloon  30  flows is formed between the outer tube  21  and the inner tube  22 , and a guide wire lumen  24  into which a guide wire  80  can be inserted is formed inside the inner tube  22 . 
     The balloon  30  has a distal side adhered to the inner tube  22 , and a proximal side adhered to the outer tube  21 . The inside of the balloon  30  communicates with the inflation lumen  23 . The balloon  30  can be deformed and inflated upon inflow of the fluid into the balloon  30 . 
     The hub  40  has a first opening portion  41  that communicates with the inflation lumen  23  of the outer tube  21  and that functions as a port for causing the inflation fluid to flow into and out of the first opening portion  41 , a second opening portion  42  that communicates with the guide wire lumen  24 , and a connection cable  43  for connecting the optical fiber  60  to the light output device  70 . The connection cable  43  is detachable from the light output device  70 . 
     The balloon  30  is preferably formed of a material having a certain degree of flexibility, and examples of such a material for the balloon  30  can include polyolefins such as polyethylene, polypropylene, polybutene, an ethylene-propylene copolymer, an ethylene-vinyl acetate copolymer, an ionomer, or a mixture of two or more of polyolefins such as polyethylene, polypropylene, polybutene, an ethylene-propylene copolymer, an ethylene-vinyl acetate copolymer, and an ionomer materials, thermoplastic resins such as a soft polyvinyl chloride resin, a polyamide, a polyamide elastomer, a polyester, a polyester elastomer, polyurethane, and a fluororesin, silicone rubber, and latex rubber. 
     The light output device  70  can output near-infrared light having any wavelength to the optical fiber  60  at any dose. The light output device  70  outputs light to the optical fiber  60  such that light can be emitted at a wavelength of, for example, 660 nm to 740 nm and a dose of, for example, 1 Jcm −2  to 50 Jcm −2 . 
     The optical fiber  60  extends from the hub  40  to the balloon  30  in the inflation lumen  23  along an outer surface of the inner tube  22 . The optical fiber  60  may include one fiber or a plurality of bundled fibers. The optical fiber  60  can receive near-infrared light from the light output device  70  via the connection cable  43  provided in the hub  40 . The optical fiber  60  has a distal end provided with an irradiation unit  61  for emitting light. 
     The irradiation unit  61  irradiates the outside with light entering from a proximal side of the optical fiber  60 . The irradiation unit  61  may be configured with, for example, a lens, a diffuser, a mirror, or the like. The irradiation unit  61  can be appropriately designed so as to be able to emit near-infrared light by using the lens, diffuser, mirror, or the like in a predetermined direction. A structure of the irradiation unit  61  is not limited as long as the irradiation unit  61  can irradiate the outside with light. 
     The irradiation unit  61  irradiates, with near-infrared light from the inside of the balloon  30 , a range including both a direction substantially perpendicular to an axis of the optical fiber  60  and a substantially distal direction (a direction parallel to the axis of the optical fiber  60 ). Therefore, near-infrared light can be emitted with a predetermined irradiation angle. Alternatively, the irradiation unit  61  may emit near-infrared light only in the direction substantially perpendicular to the axis of the optical fiber  60  or the substantially distal direction. 
     The orientation marker  50  is a site for a surgeon to confirm a position in a body. The orientation marker  50  is arranged near the balloon  30  and the irradiation unit  61 . A position where the orientation marker  50  is arranged and the number of the orientation marker  50  are not particularly limited, and for example, two orientation markers  50  are arranged on an outer peripheral surface of the inner tube  22  inside the balloon  30 . The orientation markers  50  may also be arranged on the outer tube  21 , for example. The orientation markers  50  are formed of, for example, an X-ray opaque material. The X-ray opaque material can be, for example, a metal material such as gold, platinum, or tungsten, or an alloy containing these metals. Accordingly, the surgeon can confirm the positions of the orientation markers  50  under an X-ray contrast outside the body. The orientation markers  50  may not be an X-ray contrast marker as long as the surgeon can confirm the position in the body. 
     Next, the treatment method according to the first embodiment will be described. 
     First, the antibody-photosensitive substance is administered intravenously. Approximately  12  hours to  36  hours after the intravenous administration, the surgeon inserts the guide wire  80  into the blood vessel, for example, from a femoral artery, as illustrated in  FIG. 3 . Next, a proximal end of the guide wire  80  is inserted into the guide wire lumen  24  of the irradiation device  10 , so as to cause the irradiation device  10  to reach a uterine artery UA through an internal iliac artery along the guide wire  80 . Then, the surgeon moves a distal portion of the irradiation device  10  (in particular, the irradiation unit  61 ) from a cervix U to the vicinity of a tissue or an organ infiltrated with cancer cells C while confirming the positions of the orientation markers  50  under the X-ray contrast. The tissue or the organ in which the cancer cells C are formed is the cervix, a uterine tissue, a pelvis, a bladder wall, a rectal mucosa, or the like. The surgeon arranges the distal portion of the irradiation device  10  at a position where the tissue or the organ infiltrated with the cancer cell C can be irradiated with near-infrared light. 
     Next, as illustrated in  FIG. 4 , near-infrared light is emitted from the optical fiber  60 . The irradiation with near-infrared light is started 12 hours to 36 hours after the intravenous administration. An irradiation direction of near-infrared light from the optical fiber  60  includes a direction perpendicular to the axis of the optical fiber  60 . Therefore, the optical fiber  60  can effectively irradiate the site with near-infrared light from the inside of the blood vessel to the outside of the blood vessel. The optical fiber  60  may emit near-infrared light in the distal direction. The surgeon can appropriately select the optical fiber  60  to be used according to a position of the cancer cells C with respect to the blood vessel into which the irradiation device  10  is inserted. 
     The surgeon may supply a saline (or saline solution) to the guide wire lumen  24  from a proximal side of the irradiation device  10  before emitting near-infrared light from the optical fiber  60 . Accordingly, the saline is injected (flushed) from the irradiation device  10  into the uterine artery UA. As a result, blood in the blood vessel where the distal portion of the irradiation device  10  is positioned is flushed away, which makes the irradiation with near-infrared light less likely to be influenced by the blood. Further, the surgeon may inflate the balloon  30  by supplying the inflation fluid from the inflation lumen  23  into the balloon  30  before emitting near-infrared light from the optical fiber  60 . The balloon  30  is in close contact with a blood vessel wall and blocks blood flow. Accordingly, the blood is not present between the balloon  30  and the blood vessel wall, which makes the irradiation with near-infrared light less likely to be influenced by the blood. When the balloon  30  is inflated, the surgeon discharges the inflation fluid from the balloon  30  and contracts the balloon  30  after the irradiation with near-infrared light is completed. 
     When emitting near-infrared light, near-infrared light reaches the antibody-photosensitive substance bound to cell membranes of the cancer cells C. Accordingly, a chemical change occurs to the photosensitive substance, and a structural change occurs to the antibody-photosensitive substance, whereby a hole is formed in the cell membrane, and the cancer cells C can be killed. 
     The surgeon stops emitting near-infrared light when the surgeon determines that the cancer cells C have been sufficiently killed, or that further irradiation is not desirable, or when a predetermined time has passed. 
     Next, the surgeon draws the irradiation device  10  out of the body. Then, the surgeon washes the irradiation device  10 . Accordingly, the blood is removed from the irradiation device  10 . It is preferable that the blood vessel into which the irradiation device  10  is inserted is not infiltrated with the cancer cells C. Accordingly, the cancer cells C do not attach to the irradiation device  10 , and the same irradiation device  10  can be used for a subsequent transvaginal treatment. 
     Next, the surgeon specifies a position of the cancer cells C irradiated with near-infrared ray, and records the position. It is desirable that the position of the cancer cell C is recorded as electronic data so as to correspond to position information of data such as a CT image and an MRI image of a patient acquired in advance. Accordingly, a subsequent procedure can be relatively smoothly advanced, and postoperative follow-up can be effectively performed. For example, when a plurality of the cancer cells C is irradiated with near-infrared ray, all the cancer cells C can be accurately and reliably irradiated by accurately grasping the tumor for which the irradiation with near-infrared ray is completed. The specification and recording of the position of the cancer cells C is also appropriately performed in a subsequent irradiation with near-infrared ray. 
     Next, the surgeon inserts the irradiation device  10  which is drawn out from the blood vessel and washed, into a cervical canal CC of the cervix U from a vagina V through an external uterine ostium O, as illustrated in  FIG. 5A . Accordingly, the balloon  30  is positioned in the cervical canal CC. Then, the surgeon performs irradiation with near-infrared light from the optical fiber  60 . The irradiation direction of near-infrared light from the optical fiber  60  includes the direction substantially perpendicular to the axis of the optical fiber  60 . Therefore, the optical fiber  60  can effectively irradiate the cancer cells C positioned in the cervix U with near-infrared light from the cervical canal CC. The optical fiber  60  may emit near-infrared light in the distal direction. The surgeon may insert the irradiation device  10  different from the irradiation device  10  drawn out from the blood vessel and washed into the cervical canal CC from the vagina V. When emitting near-infrared light from the cervical canal CC, since the cervical canal CC is narrow, the distal portion of the irradiation device  10  is in close contact with the cervix U. Therefore, the balloon  30  does not need to be inflated. The balloon  30  may be inflated in a lumen of the cervix U. 
     When emitting near-infrared light, near-infrared light reaches the antibody-photosensitive substance bound to the cell membranes of the cancer cells C in the cervix U. Accordingly, the chemical change of the photosensitive substance occurs, and the structural change of the antibody-photosensitive substance occurs, whereby the hole is formed in the cell membrane, and the cancer cells C in the cervix U irradiated with near-infrared light is killed. 
     The surgeon stops emitting near-infrared light when the surgeon determines that the cancer cells C have been sufficiently killed, or that further irradiation is not desirable, or when the predetermined time has passed. 
     Next, the surgeon draws out the irradiation device  10 , and draws out at least a part (or all) of the balloon  30  and the irradiation unit  61  from the external uterine ostium O. Thereafter, the surgeon supplies the inflation fluid into the balloon  30  from the inflation lumen  23  to inflate the balloon  30  as illustrated in  FIG. 5B . Then, the surgeon pushes the irradiation device  10 , and presses a distal portion of the inflated balloon  30  against a uterine vagina UV. The uterine vagina UV is a site on a vagina V side of the cervix U, and on which the external uterine ostium  0  is formed. Therefore, the balloon  30  is in close contact with the vicinity of the external uterine ostium O of the uterine vagina UV, and is inflated so as to follow a shape of the uterine vagina UV (organ). When a part of the balloon  30  is positioned in the cervical canal CC, even if the surgeon does not push the irradiation device  10 , the balloon  30  may be held in close contact with the vicinity of the external uterine ostium O of the uterine vagina UV. 
     Then, the surgeon performs irradiation with near-infrared light from the optical fiber  60 . The irradiation direction of near-infrared light from the optical fiber  60  includes the substantially distal direction and/or the direction substantially perpendicular to the axis of the optical fiber  60 . Near-infrared light emitted in the distal direction from the optical fiber  60  can effectively reach the cancer cells C positioned in the uterine vagina UV. Near-infrared light emitted in the direction perpendicular to the axis of the optical fiber  60  from the optical fiber  60  also reaches the cancer cells C positioned at a site away from the external uterine ostium O of the uterine vagina UV in a direction different from that of the irradiation illustrated in  FIG. 5A , and can effectively reach the cancer cells C positioned in the vagina V. Therefore, the optical fiber  60  can effectively emit near-infrared light to the cancer cells C positioned in the uterine vagina UV and the vagina V. 
     The surgeon stops emitting near-infrared light when the surgeon determines that the cancer cells C have been sufficiently killed, or that further irradiation is not desirable, or when a predetermined time has passed. Next, the surgeon discharges the inflation fluid from the balloon  30  to contract the balloon  30 . 
     Next, the surgeon rotates the irradiation device  10  by a predetermined angle about an axial center of the irradiation device  10 . The angle to be rotated is not particularly limited, and can be, for example, 90° to 180°. Then, the surgeon inflates the balloon  30  again in the same manner as described above, and brings the balloon  30  into close contact with the vicinity of the external uterine ostium O of the uterine vagina UV. The balloon  30  is inflated so as to follow the shape of the uterine vagina UV (organ). Thereafter, the surgeon performs irradiation with near-infrared light from the optical fiber  60 . Accordingly, the cancer cells C at different positions of the uterine vagina UV and the vagina V can be irradiated with near-infrared light by emitting near-infrared light at a place different from that before the rotation. Thereafter, the surgeon stops emitting near-infrared light. A series of processes in which the rotation of the irradiation device  10 , the inflation of the balloon  30 , the irradiation with near-infrared light, the stop of the irradiation, and the contraction of the balloon  30  are combined can be repeated once or more. This series of processes may not be performed even once. Thereafter, the surgeon draws the irradiation device  10  out of the body. Accordingly, this treatment method is ended. 
     As described above, the treatment method according to the first embodiment is a treatment method for cervical cancer, including: intravenously administering the antibody-light-absorbing substance; inserting the first irradiation device  10 , including the first optical fiber  60  and the orientation markers  50 , into the uterine artery UA 12 hours to 36 hours after the intravenous administration; advancing the irradiation device  10  to the target position while confirming the position of the first irradiation device  10  with the orientation markers  50 ; emitting near-infrared light by using the first optical fiber  60  in the direction substantially perpendicular to the first optical fiber  60 ; removing the first irradiation device  10  out of the body; inserting the second irradiation device  10 , which is the first irradiation device  10  or another irradiation device  10 , from the vagina V into the cervix U; performing irradiation by using the second optical fiber  60  included in the second irradiation device  10  in the direction substantially perpendicular to the second optical fiber  60 ; drawing at least a part of the deformation portion included in the second irradiation device  10  to the external uterine ostium O and inflating the balloon  30 , which is the deformation portion, so as to follow the shape of the organ; emitting near-infrared light by using the second optical fiber  60  in the substantially distal direction and/or the direction substantially perpendicular to the second optical fiber  60 ; and contracting the balloon  30 . 
     In the treatment method configured as described above, the first irradiation device  10  is inserted into the uterine artery UA to emit near-infrared light from the inside of the blood vessel in the substantially vertical direction, so that the tissue or the organ infiltrated with the cancer cells C near the uterine artery UA can be effectively irradiated with near-infrared light. Further, in this treatment method, the second irradiation device  10  is inserted into the narrow cervical canal CC to emit near-infrared light in the substantially vertical direction, so that the cancer cells C in the cervix U can be effectively irradiated with near-infrared light from the cervical canal CC of the cervix U. Furthermore, in this treatment method, the balloon  30 , which is the deformation portion drawn from the external uterine ostium O, is inflated to emit near-infrared light in the distal direction and/or the vertical direction, so that cervical cancer near the uterine vagina UV can be effectively irradiated with near-infrared light. Therefore, in this treatment method, the antibody-photosensitive substance bound to the cell membranes of the cancer cells C in the cervix U and the cancer cells C in the tissue or the organ infiltrated from the cervix U can be effectively irradiated with near-infrared light. This treatment method is effective not only in an early stage where the cancer cells C are confined to the cervix but also in stage IIB where the cancer cells C infiltrate into a parametrium, stage IIIA where vaginal wall infiltration reaches the lower third of the vagina, stage IIIB where the infiltration into the parametrium reaches the pelvic wall, and stage IVA where the cancer cells C infiltrate into the bladder and rectal mucosa. 
     In this treatment method, the rotating the second irradiation device  10 , the inflating the balloon  30  so as to follow the shape of the organ, the emitting near-infrared light by using the second optical fiber  60  in the substantially distal direction and/or the direction substantially perpendicular to the second optical fiber  60 , and the contracting the balloon  30  are repeated at least once after the contracting the balloon  30 , which is the deformation portion. Accordingly, in this treatment method, a wide area of the cervix U in a circumferential direction can be irradiated with near-infrared light. Further, in this treatment method, the vagina V can also be irradiated with near-infrared light in a wide area in the circumferential direction. 
     The second irradiation device  10  can be identical to the first irradiation device  10 . Accordingly, in this treatment method, the irradiation with near-infrared light from the uterine artery UA and the irradiation with near-infrared light from the cervix U can be performed by one irradiation device  10 . Therefore, this treatment method can help improve medical economics. The second irradiation device  10  may not be identical to the first irradiation device  10 . 
     In this treatment method, after the removing the first irradiation device  10  out of the body, the first irradiation device  10  is washed. Accordingly, in this treatment method, the blood attached to the first irradiation device  10  inserted into the blood vessel is removed, and the first irradiation device  10  can be placed in a desirable state to be inserted from the vagina V into the cervix U. 
     In this treatment method, the inflating the balloon  30  included in the first irradiation device  10  may be performed before the emitting near-infrared light by using the first optical fiber  60 , and the contracting the balloon  30  included in the first irradiation device  10  may be performed after the emitting near-infrared light by using the first optical fiber  60 . Accordingly, when emitting near-infrared light from the first irradiation device  10  in the uterine artery UA, the blood flow in the uterine artery UA can be blocked. Therefore, an influence of the blood on near-infrared light can be reduced, and a target site can be effectively irradiated with near-infrared light. 
     In the first embodiment, the treatment device may not be inserted into the blood vessel. That is, a modification of the treatment method according to the first embodiment is a treatment method for cervical cancer, including: intravenously administering an antibody-light-absorbing substance; inserting the second irradiation device  10  including the second optical fiber  60  from the vagina V into the cervix U 12 to 36 hours after the intravenous administration; performing irradiation by using the second optical fiber  60  included in the second irradiation device  10  in the direction substantially perpendicular to the second optical fiber  60 ; drawing at least a part of the balloon  30  included in the second irradiation device  10  to the external uterine ostium  0  and inflating the balloon  30  so as to follow the shape of the organ; emitting near-infrared light by using the second optical fiber  60  in the substantially distal direction and/or the direction substantially perpendicular to the second optical fiber  60 ; and contracting the balloon  30 . 
     In the treatment method configured as described above, the irradiation device  10  is inserted into the thin cervix U and the balloon  30  is inflated to emit near-infrared light in the distal direction and/or the vertical direction, so that cervical cancer in a wide range of the cervix U can be effectively irradiated with near-infrared light. Therefore, in this treatment method, the antibody-photosensitive substance bound to the cell membranes of the cancer cells C in the cervix U can be effectively irradiated with near-infrared light. This treatment method is effective not only in the early stage where the cancer cells C are confined to the cervix but also in stage IIA and stage IIIA where the cancer cells C infiltrate into a vaginal wall. 
     Second Embodiment 
     A treatment method according to a second embodiment is a method of inserting the irradiation device  10  from the vagina V into the cervix U, but is different from the treatment method according to the first embodiment. The irradiation device  10  to be used is the same as the irradiation device  10  used in the treatment method according to the first embodiment. 
     In the treatment method according to the second embodiment, a surgeon inserts the irradiation device  10  into the uterine artery UA, and irradiates a tissue or an organ infiltrated with the cancer cells C with near-infrared light from the uterine artery UA, in the same manner as in the first embodiment. 
     The surgeon draws the irradiation device  10  out of the body from a blood vessel, washes the irradiation device  10 , and then inserts the irradiation device  10  from the vagina V through the external uterine ostium  0  into the cervical canal CC as illustrated in  FIG. 6 . Accordingly, the distal portion of the balloon  30  is arranged in a uterine cavity UC on a side distal of an internal cervical ostium I, and a proximal portion of the balloon  30  is arranged in the vagina V on a side proximal of the external uterine ostium O. Therefore, the balloon  30  penetrates the cervical canal CC. Then, the surgeon performs irradiation with near-infrared light from the optical fiber  60 . Accordingly, the optical fiber  60  arranged in the cervical canal CC can effectively irradiate the cancer cells C positioned in the cervix U with near-infrared light. A distal portion of the optical fiber  60  arranged in the uterine cavity UC can effectively irradiate the cancer cells C positioned in the uterine cavity UC and the cervix U close to the uterine cavity UC with near-infrared light. A proximal portion of the optical fiber  60  arranged in the vagina V can effectively irradiate the cancer cells C positioned in the uterine vagina UV and the vagina V with near-infrared light. 
     As described above, the treatment method according to the second embodiment is a treatment method for cervical cancer, including: intravenously administering an antibody-light-absorbing substance; inserting the first irradiation device  10 , including the first optical fiber  60  and the orientation markers  50 , into the uterine artery UA 12 hours to 36 hours after the intravenous administration; advancing the irradiation device  10  to the target position while confirming the position of the first irradiation device  10  with the orientation markers  50 ; emitting near-infrared light by using the first optical fiber  60  in the direction substantially perpendicular to the first optical fiber  60 ; removing the first irradiation device  10  out of the body; inserting the second irradiation device  10 , which is the first irradiation device  10  or another irradiation device  10 , from the vagina V into the cervix U; inflating the balloon  30  included in the second irradiation device  10  so as to follow the shape of the organ; the emitting near-infrared light by using the second optical fiber  60  in the substantially distal direction and/or the direction substantially perpendicular to the second optical fiber  60 ; and contracting the balloon  30 . 
     In the treatment method configured as described above, the first irradiation device  10  is inserted into the uterine artery UA to emit near-infrared light from the inside of the blood vessel in the substantially vertical direction, so that the tissue or the organ infiltrated with the cancer cells C near the uterine artery UA can be effectively irradiated with near-infrared light. Further, in this treatment method, the second irradiation device  10  is inserted into the thin cervix U and the balloon  30  is inflated to emit near-infrared light in the distal direction and/or the vertical direction, so that cervical cancer in a wide range of the cervix U can be effectively irradiated with near-infrared light. Therefore, in this treatment method, the antibody-photosensitive substance bound to cell membranes of the cancer cells C at both sites such as the cervix U and the infiltrated pelvic wall can be effectively irradiated with near-infrared light. This treatment method is effective not only in an early stage where the cancer cells C are confined to the cervix but also in stage IIB where the cancer cells C infiltrate into the parametrium, stage IIIA where vaginal wall infiltration reaches the lower third of the vagina, stage IIIB where the infiltration into the parametrium reaches the pelvic wall, and stage IVA where the cancer cells C infiltrate into the bladder and the rectal mucosa. 
     In the second embodiment, the treatment device may not be inserted into the blood vessel. That is, a modification of the treatment method according to the second embodiment is a treatment method for cervical cancer, including: intravenously administering an antibody-light-absorbing substance; inserting the irradiation device  10  including the second optical fiber  60  from the vagina V into the cervix U 12 hours to 36 hours after the intravenous administration; inflating the balloon  30  included in the irradiation device  10  so as to follow the shape of the organ; emitting near-infrared light by using the optical fiber  60  in the substantially distal direction and/or the direction substantially perpendicular to the optical fiber  60 ; and contracting the balloon  30 . 
     In the treatment method configured as described above, the irradiation device  10  is inserted into the thin cervix U and the balloon  30  is inflated to emit near-infrared light in the distal direction and/or the vertical direction, so that cervical cancer in a wide range of the cervix U can be effectively irradiated with near-infrared light. Therefore, in this treatment method, the antibody-photosensitive substance bound to the cell membranes of the cancer cells C in the cervix U can be effectively irradiated with near-infrared light. This treatment method is effective not only in the early stage where the cancer cells C are confined to the cervix but also in stage IIA and stage IIIA where the cancer cells C infiltrate into the vaginal wall. 
     Further, in this treatment method, in the inflating the balloon  30 , which is a deformation portion, a part of the balloon  30  may be inflated so as to follow a shape of the uterine vagina UA on the side proximal of the external uterine ostium O. The distal portion of the balloon  30  may be positioned in the cervix U or in the uterine cavity UC. Accordingly, in this treatment method, the antibody-photosensitive substance bound to the cell membranes of the cancer cells in the cervix U including the uterine vagina UV and the tissue or the organ infiltrated downward of the cervix U can be effectively irradiated with near-infrared light. 
     Further, in this treatment method, in the inflating the balloon  30 , which is the deformation portion, the proximal portion of the balloon  30  may be inflated so as to follow the shape of the uterine vagina UV at the side proximal of the external uterine ostium O, and the distal portion of the balloon  30  may be inflated so as to follow a shape of the uterine cavity UC at the side distal of the internal cervical ostium I. Accordingly, in this treatment method, the antibody-photosensitive substance bound to the cell membranes of the cancer cells of the cervix U and the tissue or the organ infiltrated from the cervix U in the vertical direction can be effectively irradiated with near-infrared light. 
     The disclosure is not limited to the embodiments described above, and various modifications can be made by those skilled in the art within a scope of the technical idea of the disclosure. For example, as in a first modification of the irradiation device  10  illustrated in  FIG. 7A , the irradiation unit  61  of the optical fiber  60  may be arranged not in the balloon  30  but on an outer surface side of the balloon  30 . The number of the optical fiber  60  may be either one or two or more. Accordingly, a distance from the irradiation unit  61  to the cancer cells C can be shortened, so that loss of light energy can be reduced and near-infrared light can be caused to effectively reach the cancer cells C. Unlike the balloon  30 , the optical fiber  60  has no elasticity. Therefore, for example, as illustrated in  FIG. 7B , the optical fiber  60  is preferably meandered or coiled such that the optical fiber  60  can be deformed following the inflation and the contraction of the balloon  30 . 
     For example, as in a second modification of the irradiation device  10  illustrated in  FIG. 8A , the deformation portion may be at least one wire member  31  instead of the balloon  30 . The wire member  31  has a distal portion fixed to the inner tube  22 , and a proximal portion fixed to the outer tube  21 . In the second modification, the inner tube  22  and the outer tube  21  are relatively movable in the axial direction. Therefore, by bringing a distal end of the inner tube  22  and the distal end of the outer tube  21  closer to each other in the axial direction, each wire member  31  receives a compressive force, and is deformable so as to be convex outward in a radial direction, as illustrated in  FIG. 8B . Each wire member  31  has an outer surface arranged with the irradiation unit  61  of the optical fiber  60 . Therefore, a distance from the irradiation unit  61  to the cancer cells C can be shortened, so that the loss of the light energy can be reduced and near-infrared light can be caused to effectively reach the cancer cells C. 
     For example, as in a third modification of the irradiation device  10  illustrated in  FIG. 9A , the deformation portion is the balloon  30 , and the optical fiber  60  may include an inner optical fiber  62  arranged inside the balloon  30  and outer optical fibers  63  arranged on the outer surface of the balloon  30 . The inner optical fiber  62  emits near-infrared light in a substantially distal direction, for example. The outer optical fiber  63  emits near-infrared light in a range including a direction perpendicular to an axis of the outer optical fiber  63  and the distal direction. Accordingly, a distance from the irradiation unit  61  of the outer optical fiber  63  to the cancer cells C can be shortened, so that the loss of the light energy can be reduced and near-infrared light can be caused to effectively reach the cancer cells C. Further, the inner optical fiber  62  can effectively perform irradiation in the distal direction. Unlike the balloon  30 , the outer optical fiber  63  has no elasticity. Therefore, for example, as illustrated in  FIG. 9B , the outer optical fiber  63  is preferably meandered or coiled such that the outer optical fiber  63  can be deformed following the inflation and the contraction of the balloon  30 . 
     The detailed description above describes embodiments of an irradiation device used for treatment of cervical cancer and a treatment method for cervical cancer. The invention is not limited, however, to the precise embodiments and variations described. Various changes, modifications and equivalents may occur to one skilled in the art without departing from the spirit and scope of the invention as defined in the accompanying claims. It is expressly intended that all such changes, modifications and equivalents which fall within the scope of the claims are embraced by the claims.